Document is current
Any future updates will be listed below
-
Authors
Che, Meixia
Chaturvedi, Aashi
Munro, Sarah A.
Pitzen, Samuel P. http://orcid.org/0000-0001-6556-0461
Ling, Alex http://orcid.org/0000-0001-6194-9875
Zhang, Weijie
Mentzer, Josh
Ku, Sheng-Yu http://orcid.org/0000-0003-4715-1888
Puca, Loredana
Zhu, Yanyun
Bergman, Andries M. http://orcid.org/0000-0001-5223-2549
Severson, Tesa M.
Forster, Colleen
Liu, Yuzhen
Hildebrand, Jacob
Daniel, Mark
Wang, Ting-You
Selth, Luke A.
Hickey, Theresa http://orcid.org/0000-0002-2752-730X
Zoubeidi, Amina http://orcid.org/0000-0002-0498-142X
Gleave, Martin
Bareja, Rohan
Sboner, Andrea http://orcid.org/0000-0001-6915-3070
Tilley, Wayne http://orcid.org/0000-0003-1893-2626
Carroll, Jason S. http://orcid.org/0000-0003-3643-0080
Tan, Winston
Kohli, Manish
Yang, Rendong http://orcid.org/0000-0002-9512-2240
Hsieh, Andrew C. http://orcid.org/0000-0002-0897-1050
Murugan, Paari
Zwart, Wilbert http://orcid.org/0000-0002-9823-7289
Beltran, Himisha
Huang, R. Stephanie http://orcid.org/0000-0002-9862-0368
Dehm, Scott M. http://orcid.org/0000-0002-7827-5579
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA174777)
- License Information
-
More Information
Article History
Received: 16 August 2021
Accepted: 4 October 2021
First Online: 4 November 2021
Competing interests
: L.P. is an employee of Loxo Oncology at Lilly, this work was completed prior to her employment at Loxo, she is acting on her own, and these endeavors are not in an manner affiliated with Loxo Oncology at Lilly. H.B. has received research funding from Janssen, Abbvie Stemcentryx, Astellas, Eli Lilly, Millenium and has served as advisor/consultant for Janssen, Astellas, Amgen, Astra Zeneca, Pfizer, Sanofi Genzyme. A.C.H. has received research funding from eFFECTOR Therapeutics. S.M.D. is principal investigator on grants to University of Minnesota from Astellas/Pfizer and Janssen. S.M.D. has served as advisor/consultant for Celgene/Bristol Myers Squibb, Janssen, and Oncternal Therapeutics.
